Memantine with or without raloxifene to help protect memory during brain radiation
Original title: Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a mid stage study in people, and the answer is not known yet.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests whether adding a second drug helps delay memory problems during brain radiation.
Who this trial is for. This trial is for adults over the age of 18 who will get radiation for brain cancer. It tests memantine: A medicine given with whole-brain radiation to help protect thinking and memory. See the glossary alone against memantine plus raloxifene.
Where it stands. The trial is measuring how long it takes for memory problems to start. That answer is not in yet. The trial has not reported results.
What this means, and what it doesn't
What it could mean: Someone who fits could ask their care team about this study. The goal is to learn how to protect memory during brain radiation.
What it doesn't mean: A trial is a test, not a proven treatment. Being in one is not a promise that it will help you. It is not a cure, and it is not a promise of one.
Source: ClinicalTrials.gov, September 22, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.